Patient Listening Session Summaries
The FDA published high-level summaries of Patient Listening Sessions, noting that the agency drafts summaries for FDA-requested sessions while patient community requesters draft summaries for patient-led sessions.
This affects manufacturers of biological products and medical therapies, specifically regulatory affairs, clinical operations, and patient engagement departments involved in assessing patient-reported outcomes and disease-specific burdens.
These summaries provide formal documentation of patient perspectives on specific diseases and treatment experiences. For regulatory professionals, these documents likely offer insight into how the FDA and patient communities view unmet needs, which may influence clinical trial design or the development of patient-focused drug development (PFDD) initiatives. The distinction in authorship suggests that industry should be mindful of the source—either the FDA or a patient group—when evaluating the context of the feedback.
Regulatory and clinical teams should monitor published summaries from relevant listening sessions to identify emerging patient priorities and potential areas for endpoint refinement. Industry sponsors should consider these summaries as supplemental sources for understanding patient-centric definitions of benefit and risk.
Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.
Open in openFDA / FDA.gov